Clin Osteol 2009; 14(1): 7-10

Oestrogen hormone replacement therapy to prevent osteoporosisReview articles

M. Borovský

The use of hormone therapy in the prevention of osteoporosis has beenjustified by data from biology, epidemiology, preclinical as well as observational and randomized clinical studies. Reduction of the clinical impact of oestrogen deficiency by their replacement is sta­ tistically significant, clinically relevant and biologically explained. Low-dose hormone replacement therapy in postmenopausal women minimizes potential side effects and probably increases compliance. Also, low doses of oestrogen may at least reduce potential thera­ py-associated risks while maintaining the positives of conventional hormone therapy. At present, prevention of osteoporosis may be considered the most important additional effect of postmenopausal hormone therapy.

Keywords: postmenopause, osteoporosis, hormone therapy

Published: June 11, 2009  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Borovský M. Oestrogen hormone replacement therapy to prevent osteoporosis. Osteologický bulletin. 2009;14(1):7-10.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Pines A, 11:443-446.
    2. Lindsay R, Hart DM, Aitken JM, et al. Long-term prevention of postmenopausal osteoporosis by oestrogen. Evidence for an increas set of oestrogen treatment. Lancet 1976;1:1038-41. Go to original source...
    3. Gambacciani M, Spinetti A, de Simone L, et al. The relative contribution nopause and aging to postmenopausal vertebral osteopenia. J Clin Endocrinol Metab 1993;77:1148-51. Go to original source...
    4. Stone K, Bauer DC, Black DM, et al. Hormonal predictors of bone loss in e ly women: a prospective study, The Study of Osteoporotic Fractures Research Group. J Bone Miner Res. 1998;13:1167-1174. Go to original source...
    5. Cummings SR, Browner WS, Bauer D, et al. Endogenous hormones and the risk of hip and vertebral fractures among older women. Study of Osteoporotic Fractures Research Group. N Engl J Med 1998;339:733-738. Go to original source...
    6. Mastalgia SR, Bagur A, Royer M et al.: Effect of endogenous estradiol bone resorption and bone mineral density in healthy postmenopausal women: a prospective study. Climacteric 2009;12:49-58. Go to original source...
    7. Cauley JA, Robbins J, Chen Z et al. Effects of estrogen plus progestin on ris fracture and bone mineral density. The Women's Health Initiative randomized tri­ al. JAMA 2003;290:1729-38. Go to original source...
    8. Rossouw JE, Anderson GL, Prentice RL, et al. Writing Group for the Women's Health Initiative Investigators. Risk and benefits of estrogen plus proge althy postmenopausal women. JAMA 2002;288:321-33. Go to original source...
    9. UK General Practice Research Database support WHI trial results. Human Reproduction 2007;22:1769-77.
    10. Ettinger B, Genant HK, Steiger P, et al. Low-dosage micronized 17 beta-estra prevents bone loss in postmenopausal women. Am J Obstet Gynecol 1992;166:479 488. Go to original source...
    11. Gambacciani M, Cappagli B, Ciaponi M et al.: Ultra low-dose hormone replace­ ment therapy and bone protection in postmenopausal women. Maturitas 2008;59:2-6. Go to original source...
    12. Ettinger B, Ensrud KE, Wallace R, et al. Effects of ultralow-dose transdermal radiol on bone mineral density: a randomized clinical trial. Obstet Gynecol 2004;104:443-51. Go to original source...
    13. Bagger YZ, Tanko LB, Alexandersen P, et al. Two to three years of hormone re­ placement treatment in healthy women have long-term preventive effects on bone mass and osteoporotic fractures: the PERF study. Bone 2004;34:728-735. Go to original source...
    14. Hersh AL, Stefanick ML, Stafford RS. National use of postmenopausal hormone therapy: annual trends and response to recent evidence. JAMA, 2004;291:47-53.
    15. Gambacciani M, Ciaponi M, Gennazzani AR.: The HRT misuse and osteoporosis epidemic: a possible future scenario. Climacteric 2007;10:273-275. Go to original source...
    16. Siris ES, Miller PD, Barret-Connor E, et al.: Identification and fracture outc of undiagnosed low bone mineral density in postmenopausal women: results from the National Osteoporosis Risk assessment. JAMA 2001;286:2815-22. Go to original source...
    17. Neer RM, Arnaud CD, Zanchetta JR, et al.: Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporo­ sis. N Engl J Med 2001;344:1434-41. Go to original source...
    18. Barlow DH: What is the optimal policy for osteoporosis managment? Maturitas 2008;60:3-9. Go to original source...
    19. Birkhäuser MH, Panay N, Archer DF et al.: Updated practical recommendations for hormone replacement therapy in the peri- and postmenopause. Climacteric 2008;11:108-123. Go to original source...
    20. Bayer M, Jeníček J, Kučerová I et al.: Doporučené postupy pro diagnostiku a terapii postmenopauzální osteoporózy II, část první. Osteol bull 2007;1:24-34.
    21. Bayer M, Jeníček J, Kučerová I et al.: Doporučené postupy pro diagnostiku a terapii postmenopauzální osteoporózy II, část druhá. Osteol bull 2007;2:74-81.

    Return to the content


    Clinical Osteology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.